Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
133 hedge funds and large institutions have $485M invested in Cymabay Therapeutics in 2019 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 54 increasing their positions, 29 reducing their positions, and 32 closing their positions.
511% more call options, than puts
Call options by funds: $7.81M | Put options by funds: $1.28M
86% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 29
6% less funds holding
Funds holding: 142 → 133 (-9)
22% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 32
47% less capital invested
Capital invested by funds: $907M → $485M (-$422M)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$44.1M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$22.4M |
| 3 |
Millennium Management
New York
|
+$14.5M |
| 4 |
Citigroup
New York
|
+$6.37M |
| 5 |
BlackRock
New York
|
+$5.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$24.9M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$13.3M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
-$11.1M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.5M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$8.91M |
CBAY Hedge Fund Activity: Q2 2019 in Review
133 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q2 2019, worth a combined $485M — down 47% from $907M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of CBAY and 25 opened new positions — a net loss of 7 holders — while 29 trimmed existing stakes and 54 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $44.1M. The largest seller was OrbiMed, exiting entirely with an estimated $24.9M sold.
- 133 institutional investors held Cymabay Therapeutics (CBAY) as of Q2 2019, down from 142 in Q1 2019.
- Funds reported $485M of Cymabay Therapeutics stock for Q2 2019, down 47% quarter-over-quarter.
- 25 funds opened new Cymabay Therapeutics positions in Q2 2019 and 32 closed out, a net change of -7 holders.
- The largest Cymabay Therapeutics buyer in Q2 2019 was Point72 Asset Management, an estimated $44.1M added.
- The largest Cymabay Therapeutics seller in Q2 2019 was OrbiMed, an estimated $24.9M sold.
Based on aggregated 13F filings for Q2 2019.